Friday, February 7, 2014

Comparison of 3D Cell Culture Technologies to Plated Cells in 2D for Oncology and Toxicology Applications

A central focus for improving drug efficacy in clinical trials over the last decade has been to increase the biological relevance of assays performed early in the drug discovery process. Yet it remains difficult to simulate an in vivo response to drug using an in vitro assay, where the cells are grown on hard plastic or glass substrates, in a two-dimensional (2D) format which is not representative of the in vivo cellular environment. When examining cells within a tissue, it can be observed that cells interact with neighboring cells, and with the extracellular matrix (ECM) to form a communication network. This communication controls a number of cellular processes including proliferation, migration, and apoptosis. However, most of the tissue-specific architecture, cell-cell communication, and cues are lost when cells are grown in a more simplified 2D manner. Therefore, more advanced cell culture methods are required to better mimic cellular function within living tissue.

3D cell culture serves to meet this demand by providing a matrix that encourages cells to reorganize into a structure more indicative of an in vivo environment; thereby allowing normal cell-cell and cell-ECM interactions to develop in an in vitro environment.

In an upcoming webinar to be presented on February 27, we will describe two common formats for culturing cells into 3D. These include the RAFT™ collagen-based 3D cell culture system from TAP Biosystems (Hertfordshire, UK) and GravityPLUS™ platform from InSphero (Schlieren, Switzerland). Individual project results will demonstrate how these 3D cell culturing procedures can be automated using the non-contact dispensing capabilities of the MultiFlo™ FX, and microplate reading and imaging-based assays can be performed using the Cytation™ 3 to generate more relevant data for oncology and toxicology studies than traditional 2D methods.

Register for the webinar to learn more.

By: BioTek Instruments, Brad Larson, Principal Scientist

No comments:

Post a Comment